Why is Parmax Pharma Ltd ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 1.09% and Operating profit at 6.65% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.66
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 323.51%, its profits have risen by 129% ; the PEG ratio of the company is 0.8
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Parmax Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Parmax Pharma
323.51%
4.22
76.74%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
1.09%
EBIT Growth (5y)
-207.17%
EBIT to Interest (avg)
0.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.77
Sales to Capital Employed (avg)
2.44
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-28.89%
ROE (avg)
5.12%
Valuation Key Factors 
Factor
Value
P/E Ratio
88
Industry P/E
24
Price to Book Value
-15.11
EV to EBIT
-27.61
EV to EBITDA
-45.73
EV to Capital Employed
21.99
EV to Sales
3.77
PEG Ratio
0.76
Dividend Yield
NA
ROCE (Latest)
-97.46%
ROE (Latest)
Negative BV
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Bullish
Technical Movement
22What is working for the Company
NET SALES(Latest six months)
Higher at Rs 19.92 cr
PAT(Latest six months)
Higher at Rs 2.37 cr
-4What is not working for the Company
OPERATING CF(Y)
Lowest at Rs -2.36 Cr
NON-OPERATING INCOME(Q)
is 1,323.53 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Parmax Pharma
Net Sales - Latest six months
At Rs 19.92 cr has Grown at 345.64%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
At Rs 2.37 cr has Grown at 183.45%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Net Sales - Latest six months
Higher at Rs 19.92 cr
than preceding 12 month period ended Sep 2026 of Rs 12.11 crMOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 2.37 cr
than preceding 12 month period ended Sep 2026 of Rs -4.15 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
Here's what is not working for Parmax Pharma
Operating Cash Flow - Annually
Lowest at Rs -2.36 Cr and Fallen
each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (Rs Cr)
Non Operating Income - Quarterly
is 1,323.53 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT